Cure8 research brief
Many pediatric patients with IBD receive infusion biologic therapies. Shifts in where those infusions happen (driven by payer policies) can create administrative burdens and raise concerns about safety and care coordination.
Pediatric IBD clinicians, infusion nurses and centers, caregivers of children receiving biologic infusions, and policymakers or payer decision-makers involved in site-of-care policies.
This abstract reports a national anonymous web-based survey of pediatric GI clinicians about site-of-care shifts for infusion biologics (Feb 2026).
Respondents rated prior authorization/payer friction as the top pain point and prioritized infusion-site safety (reaction management), reliable communication back to the GI team, patient experience, and pediatric infusion expertise when alternative infusion sites are used.
The survey summarizes clinician perceptions and decision drivers but does not report patient-level outcomes. It reflects clinician experience and attitudes rather than measured safety or efficacy differences across sites.
Practical takeaways: administrative burden (prior auth/payer processes) is a major barrier to site-of-care shifts; safety capability and bidirectional communication are viewed as critical when infusions move away from hospital outpatient departments.
This is a clinician survey (JPGN reports abstract). It captures perceptions and priorities but does not provide direct safety or outcome data comparing infusion sites. Findings reflect respondent views (n=100) collected via a pediatric GI listserv in Feb 2026.
Review the original publication for the complete reporting, methods, and context.
Conflict statement: The authors declare no conflict of interest.
This Cure8 brief is based on source text from the linked article. Cure8 is informational only and is not a substitute for professional medical advice, diagnosis, or treatment.
Avoidable unplanned hospital admissions are common and costly for people with IBD. This study suggests many such admissions stem from healthcare access and service delivery problems—not just disease severity—so system...
This is relevant because military aviators with Crohn’s disease have historically been excluded from waivers; policy changes could allow some stable patients to continue flying if objective evidence supports low...
Biosimilars can expand access to effective biologic treatment for people with IBD by reducing costs, but adoption barriers mean some patients may not benefit. Understanding evidence, practical concerns, and...
